Japan Approves Dupixent for Chronic Spontaneous Urticaria (CSU) Becoming First in the World to Do So
This makes CSU treatment the sixth approved use globally.
japanese flag © somartin - stock.adobe.com
The Ministry of Health, Labor and Welfare (MHLW) in Japan granted marketing and manufacturing authorization for Dupixent (dupilumab) to treat chronic spontaneous urticaria (CSU), according to today’s Regeneron and Sanofi press release.
CSU is characterized by recurrent and itchy hives often triggered by temperature or pressure on the skin. Both adults and children can be affected but it is twice as common in adult females. It is associated with immune disorders like food allergies and hypothyroidism.
About 110,000 people in Japan aged 12 years and older currently suffer from uncontrolled moderate to severe CSU. In the United States, 1% of the population is affected at any given time.
Dupixent is also used to treat atopic dermatitis and asthma with 800,000 being treated globally.
Combined Oral and Phototherapy Treatments Show Promise in Treating Severe Vitiligo
January 21st 2025In a phase 2 clinical trial, researchers examined baricitinib and NB-UVB in adults with severe vitiligo in the dermatology departments at 4 hospitals in France between July 2021 and April 2023.
Read More
Diverse, Nutritious Early Diet May Ease Childhood Persistent Atopic Dermatitis
January 15th 2025A South Korean study explored the link between lifestyle decisions beginning in infancy and persistent atopic dermatitis, citing exclusive breast milk diet and childhood obesity as potential factors.
Read More
